KR101756935B1 - 이중 가교를 갖는 하이드로젤 지지체, 그의 용도 및 이단계 가교를 사용하여 그를 제조하는 하는 방법 - Google Patents
이중 가교를 갖는 하이드로젤 지지체, 그의 용도 및 이단계 가교를 사용하여 그를 제조하는 하는 방법 Download PDFInfo
- Publication number
- KR101756935B1 KR101756935B1 KR1020150188915A KR20150188915A KR101756935B1 KR 101756935 B1 KR101756935 B1 KR 101756935B1 KR 1020150188915 A KR1020150188915 A KR 1020150188915A KR 20150188915 A KR20150188915 A KR 20150188915A KR 101756935 B1 KR101756935 B1 KR 101756935B1
- Authority
- KR
- South Korea
- Prior art keywords
- gelatin
- crosslinking
- alginate
- cell
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 93
- 238000004132 cross linking Methods 0.000 title claims abstract description 65
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 12
- 238000004113 cell culture Methods 0.000 claims abstract description 10
- 238000010382 chemical cross-linking Methods 0.000 claims abstract description 7
- 229920000615 alginic acid Polymers 0.000 claims description 72
- 229920000159 gelatin Polymers 0.000 claims description 70
- 235000019322 gelatine Nutrition 0.000 claims description 69
- 108010010803 Gelatin Proteins 0.000 claims description 68
- 239000008273 gelatin Substances 0.000 claims description 68
- 235000011852 gelatine desserts Nutrition 0.000 claims description 68
- 229940072056 alginate Drugs 0.000 claims description 66
- 235000010443 alginic acid Nutrition 0.000 claims description 62
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 55
- 230000004069 differentiation Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000007639 printing Methods 0.000 claims description 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 4
- 238000001879 gelation Methods 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 230000000704 physical effect Effects 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 24
- 210000000988 bone and bone Anatomy 0.000 description 18
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 12
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 210000000663 muscle cell Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000000783 alginic acid Substances 0.000 description 5
- 229960001126 alginic acid Drugs 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010064211 Bone fragmentation Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GKXJWSZPLIKUPS-IUNAMMOKSA-N N-[(2Z,6Z)-2,6-bis(hydroxyimino)cyclohexylidene]hydroxylamine Chemical compound O\N=C1\CCC\C(=N\O)C1=NO GKXJWSZPLIKUPS-IUNAMMOKSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010017 direct printing Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/222—Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
도 2는 일 구체예에 따른 하이드로젤 지지체에서 배양된 근육아세포를 개수한 결과를 나타낸 그래프이다.
도 3은 일 구체예에 따른 하이드로젤 지지체에서 배양된 근육아세포를 관찰한 현미경 사진이다.
도 4는 일 구체예에 따른 하이드로젤 지지체에서 배양된 인간 중간엽줄기세포를 관찰한 현미경 사진이다.
도 5는 일 구체예에 따른 하이드로젤 지지체에서 근육 조직으로 분화시킨 결과를 나타낸 사진이다.
도 6은 일 구체예에 따른 하이드로젤 지지체에서 인간 중간엽줄기세포를 골조직으로 분화시킨 결과를 나타낸 사진이다.
도 7은 일 구체예에 따른 하이드로젤 지지체에서 인간 중간엽줄기세포를 골 조직으로 분화시켜 ALP 어세이를 수행한 결과를 나타낸 그래프이다.
도 8은 일 구체예에 따른 하이드로젤 지지체의 바이오 프린팅을 위한 바이오 잉크로서의 사용을 나타낸 사진이다.
Claims (16)
- 하이드로젤 지지체 전체에 대하여 0.5 내지 20 중량%의 알지네이트, 0.5 내지 20 중량%의 젤라틴, 및 60 내지 99 중량%의 수분을 포함하고,
상기 젤라틴의 가교제를 포함하지 않고,
상기 알지네이트 및 젤라틴은 각각 가교된 것이며, 및
상기 가교된 젤라틴에 의해 알지네이트가 고정되고, 상기 가교된 알지네이트에 의해 젤라틴이 고정되어 있는 것인 하이드로젤 지지체. - 삭제
- 청구항 1에 있어서, 상기 알지네이트 및 젤라틴 각각의 가교인 이중 가교에 의해 세포 배양 또는 세포 분화 온도에서 겔화의 상태를 유지하는 것인 하이드로젤 지지체.
- 청구항 1에 있어서, 상기 가교는 화학적 가교제 의한 것이 아닌 물리적 가교인 것인 하이드로젤 지지체.
- 청구항 1에 있어서, 상기 하이드로젤 지지체에 세포, 성장인자 또는 분화인자가 더 포함되어 있는 것인 하이드로젤 지지체.
- 청구항 5에 있어서, 상기 세포는 줄기세포, 감각세포, 뇌세포, 생식세포, 상피세포, 면역세포, 암세포 또는 그의 조합인 것인 하이드로젤 지지체.
- 청구항 5에 있어서, 상기 성장인자는 형질전환성장인자(TGF), 혈관내피 성장인자(VEGF), 섬유아세포 성장인자(FGF), 표피 성장인자(EGF), 혈소판-유도 내피 성장인자(PDGF), 간세포 성장인자 (HGF), 인슐린 유사 성장인자 (IGF), 사이토카인, 캐모카인 또는 그의 조합인 것인 하이드로젤 지지체.
- 삭제
- 청구항 1에 있어서, 생체조직 재생을 위한 것인 하이드로젤 지지체.
- 청구항 1의 하이드로젤 지지체를 포함하는 바이오프린팅을 위한 바이오잉크 조성물.
- 젤라틴 및 알지네이트를 혼합하여 젤라틴-알지네이트 용액을 형성하는 단계; 및
상기 젤라틴-알지네이트 용액에 이단계 가교를 수행하여 하이드로젤 지지체 전체에 대하여 0.5 내지 20 중량%의 알지네이트, 0.5 내지 20 중량%의 젤라틴, 및 60 내지 99 중량%의 수분을 포함하는 하이드로젤 지지체를 형성하는 단계로서, 상기 젤라틴을 2 내지 10 ℃의 온도에서 겔화하여 젤라틴을 가교하는 단계 및, 알지네이트를 가교하는 단계를 포함하는 것인 단계를 포함하고,
상기 젤라틴을 가교하는 단계는 젤라틴의 가교제를 첨가하는 단계를 포함하지 않는 것이고, 및
상기 가교된 젤라틴에 의해 알지네이트가 고정되고, 상기 가교된 알지네이트에 의해 젤라틴이 고정되어 있는 것인 하이드로젤 지지체를 제조하는 방법. - 청구항 11에 있어서, 상기 젤라틴-알지네이트 용액에 세포 또는 성장인자를 혼합하는 단계를 더 포함하는 것인 방법.
- 삭제
- 청구항 11에 있어서, 상기 알지네이트를 가교하는 단계는 이온 가교, 공유 가교, 광 가교, 또는 세포 가교에 의한 것인 방법.
- 청구항 12에 있어서, 상기 세포가 포함된 하이드로젤 지지체를 배양 배지 중 배양하거나, 또는 분화 유도 배지 중 분화시키는 단계를 더 포함하는 것인 방법.
- 청구항 11에 있어서, 상기 알지네이트 및 젤라틴 각각의 이단계 가교에 의해 세포 배양 또는 세포 분화 온도에서 겔화의 상태를 유지하는 것인 방법.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150188915A KR101756935B1 (ko) | 2015-12-29 | 2015-12-29 | 이중 가교를 갖는 하이드로젤 지지체, 그의 용도 및 이단계 가교를 사용하여 그를 제조하는 하는 방법 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150188915A KR101756935B1 (ko) | 2015-12-29 | 2015-12-29 | 이중 가교를 갖는 하이드로젤 지지체, 그의 용도 및 이단계 가교를 사용하여 그를 제조하는 하는 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170078417A KR20170078417A (ko) | 2017-07-07 |
| KR101756935B1 true KR101756935B1 (ko) | 2017-07-26 |
Family
ID=59353295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150188915A Active KR101756935B1 (ko) | 2015-12-29 | 2015-12-29 | 이중 가교를 갖는 하이드로젤 지지체, 그의 용도 및 이단계 가교를 사용하여 그를 제조하는 하는 방법 |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101756935B1 (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210004222A (ko) * | 2019-07-03 | 2021-01-13 | 서울과학기술대학교 산학협력단 | 알지네이트-히알론산 하이드로젤 및 이의 제조방법 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102279913B1 (ko) * | 2018-05-23 | 2021-07-21 | 포항공과대학교 산학협력단 | 이중가교성 화합물을 이용한 동맥류 색전술용 조성물 및 그 제조방법 |
| WO2021006669A1 (ko) * | 2019-07-10 | 2021-01-14 | 사회복지법인 삼성생명공익재단 | 연골조직 형성용 바이오잉크 조성물 |
| WO2021006664A1 (ko) * | 2019-07-10 | 2021-01-14 | 사회복지법인 삼성생명공익재단 | 골조직 형성용 바이오잉크 조성물 |
| US12252711B2 (en) | 2019-07-25 | 2025-03-18 | Medifab Co., Ltd. | Osteoporosis model comprising calcium phosphate hydrogel composition and use thereof |
| KR102095485B1 (ko) * | 2019-07-25 | 2020-03-31 | 주식회사 메디팹 | 인산칼슘 하이드로겔 조성물을 포함하는 골다공증 모델 및 이의 용도 |
| KR102099842B1 (ko) * | 2019-09-26 | 2020-04-10 | (주)리젠바이오참 | 조직재생용 하이드로겔 조성물 및 이를 이용하여 제조된 지지체 |
| CN111087628A (zh) * | 2019-12-31 | 2020-05-01 | 杭州彗搏科技有限公司 | 一种用于骨修复的水凝胶及其制备方法 |
| KR102493436B1 (ko) * | 2020-02-18 | 2023-01-31 | 주식회사 메디팹 | 수축 제어가 가능한 진피층 개발, 및 이를 이용한 균일한 성능의 인공피부 의 제조 |
| KR102468837B1 (ko) * | 2020-07-14 | 2022-11-18 | 주식회사 피씨지바이오 | 생체적합성 하이드로겔을 포함하는 온도 감응형 복합 하이드로겔 시트 |
| KR102735335B1 (ko) * | 2020-09-23 | 2024-11-29 | 연세대학교 산학협력단 | 배양육 제조용 다공성 세포배양 지지체, 이를 이용한 배양육 제조방법 및 배양육을 포함하는 특수 가공식품 |
| CN112778544B (zh) | 2021-01-21 | 2021-12-03 | 江南大学 | 用于肌肉干细胞培养的交联水凝胶及其制备方法和应用 |
| KR102435091B1 (ko) * | 2022-03-08 | 2022-08-23 | (주)안트로젠 | 이중가교된 하이드로겔 스캐폴드를 이용한 성장인자 함량이 증가된 줄기세포 배양액 제조방법 및 이로부터 얻어진 조성물 |
| KR20250146682A (ko) | 2024-04-02 | 2025-10-13 | 한국식품연구원 | 해양 유래 단백질을 포함하는 다공성 세포 지지체의 제조방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007100475A2 (en) | 2006-02-23 | 2007-09-07 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
-
2015
- 2015-12-29 KR KR1020150188915A patent/KR101756935B1/ko active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007100475A2 (en) | 2006-02-23 | 2007-09-07 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
Non-Patent Citations (1)
| Title |
|---|
| WEN, C. et al., Macromol. Mater. Eng.(2014) Vol.299, pp.504-513* |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210004222A (ko) * | 2019-07-03 | 2021-01-13 | 서울과학기술대학교 산학협력단 | 알지네이트-히알론산 하이드로젤 및 이의 제조방법 |
| KR102261820B1 (ko) | 2019-07-03 | 2021-06-07 | 서울과학기술대학교 산학협력단 | 알지네이트-히알론산 하이드로젤 및 이의 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170078417A (ko) | 2017-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101756935B1 (ko) | 이중 가교를 갖는 하이드로젤 지지체, 그의 용도 및 이단계 가교를 사용하여 그를 제조하는 하는 방법 | |
| US11511016B2 (en) | Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery | |
| US20220218873A1 (en) | Hyaluronic acid and gelatin-containing formulations | |
| JP6762936B2 (ja) | 軟骨修復のための移植片足場及びその製造方法 | |
| Zhang et al. | Application of hydrogels in heart valve tissue engineering | |
| Farhat et al. | Hydrogels for advanced stem cell therapies: a biomimetic materials approach for enhancing natural tissue function | |
| US8883503B2 (en) | Hydrogel scaffolds for tissue engineering | |
| JP6055466B2 (ja) | 酸化オリゴ糖で架橋したゲル材料 | |
| Chen et al. | Hyaluronic acid-based biphasic scaffold with layer-specific induction capacity for osteochondral defect regeneration | |
| Pal et al. | Biofabrication paradigms in corneal regeneration: bridging bioprinting techniques, natural bioinks, and stem cell therapeutics | |
| KR101877892B1 (ko) | 이중가교를 갖는 3차원 세포배양 지지체 제조방법 | |
| CN108310463A (zh) | 一种3d打印生物墨水及其制备方法 | |
| EP4499160B9 (en) | Use of polymer-based microcarriers in the production of tissue scaffolds with complex geometry | |
| Tomić et al. | Hydrogel Scaffolds Based on Alginate, Gelatin, and 2-Hydroxyethyl Methacrylate for Tissue Regeneration | |
| Dalal et al. | The progress in tissue engineering of kidney | |
| Szymkowiak | In Vitro Perfused Tissue Engineered Kidney Constructs | |
| Kang | Biofabricated platforms for wound healing and skin regeneration | |
| KR20240114492A (ko) | 면역분극화된 엑소좀 기반 삼차원 바이오프린팅된 하이드로겔 제조용 바이오잉크 조성물 및 그 응용 | |
| KR20250018028A (ko) | 생체 반응성 하이드로겔을 포함하는 바이오 잉크 조성물 및 그 제조 방법 | |
| Kesti | Bioprinting technologies for auricular cartilage tissue engineering | |
| HK1144182B (en) | Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20151229 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170417 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170703 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20170705 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20170706 End annual number: 3 Start annual number: 1 |
|
| PG1501 | Laying open of application | ||
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20200701 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210617 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220630 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230921 Start annual number: 7 End annual number: 7 |